In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Edoxaban vs warfarin in vitamin K antagonist experienced and naive patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial

Session Poster Session 2

Speaker Gregory Yh Lip

Congress : ESC Congress 2018

  • Topic : arrhythmias and device therapy
  • Sub-topic : Rhythm Control, Cardioversion
  • Session type : Poster Session
  • FP Number : P1923

Authors : GYH Lip (Birmingham,GB), N Al-Saady (Maidenshead,GB), SP Hjortshoj (Aalborg,DK), A Goudev (Sofia,BG), K Huber (Vienna,AT), A-A Cohen (Paris,FR), J Jin (Basking Ridge,US), M Merino (Basking Ridge,US), S M Winters (Basking Ridge,US), A Goette (Paderborn,DE)

Authors:
G.Y.H. Lip1 , N. Al-Saady2 , S.P. Hjortshoj3 , A. Goudev4 , K. Huber5 , A.-A. Cohen6 , J. Jin7 , M. Merino7 , S.M. Winters8 , A. Goette9 , 1University of Birmingham - Birmingham - United Kingdom , 2Covance Inc. - Maidenshead - United Kingdom , 3Aalborg University - Aalborg - Denmark , 4Queen Giovanna University Hospital - Sofia - Bulgaria , 5Wilhelminen Hospital - Vienna - Austria , 6University Pierre & Marie Curie Paris VI - Paris - France , 7Daichii Sankyo Pharma Development - Basking Ridge - United States of America , 8Daiichi Sankyo, Inc, Global Medical Affairs - Basking Ridge - United States of America , 9St. Vincenz-Hospital - Paderborn - Germany ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 414

Background: In the ENSURE-AF study (NCT 02072434), the oral factor Xa inhibitor edoxaban showed a similar efficacy and safety profile vs enoxaparin–warfarin (enox–warf) in patients undergoing electrical cardioversion of nonvalvular atrial fibrillation.

Methods: This prespecified ancillary analysis examined the efficacy and safety of edoxaban vs enox–warf in patients who were vitamin K antagonist (VKA) naïve or experienced at the time of randomisation in the ENSURE-AF study. The primary efficacy endpoint was a composite of stroke, systemic embolic event (SEE), myocardial infarction (MI), and cardiovascular death analysed during the overall study period, 28 days on study drug after cardioversion + 30 days follow-up. The primary safety endpoint was the composite of major and clinically relevant nonmajor bleeding analysed during the on-treatment period from the time of first dose to last dose of study drug taken + 3 days.

Results: Of 2,199 patients enrolled in ENSURE-AF, 1,095 were randomised to edoxaban and 1,104 to enox–warf. Mean age was 64±10 years and 64.2±11 years, respectively. Baseline characteristics were similar for patients who were VKA naïve and experienced vs the comparative edoxaban treatment arm. There were fewer primary efficacy endpoint events with edoxaban than enox–warf in VKA experienced or naïve. There were no significant differences in bleeding rates regardless of treatment or VKA experience (Table).

Conclusion: In the ENSURE-AF study, edoxaban had comparable efficacy and safety to optimized usual anticoagulation with enox–warf. The primary efficacy endpoint outcomes were not significantly different between patients who were VKA experienced or naïve.

Table 1

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are